Image courtesy of Elekta · official image bank
up to €100m · Debt · Healthtech · Stockholm, Sweden
Stockholm-based medical-technology company Elekta has secured up to €100m in debt financing from the European Investment Bank to support research and development in radiotherapy, radiosurgery, brachytherapy and the software used to plan and deliver treatment. The EIB announced the loan on 31 August, after signing two tranches totalling €100m on 24 August.
The facility will cover up to half of a roughly €200m research programme running from 2026 to 2029. EIB project records allocate €76m of the loan to work in Sweden and €24m to the Netherlands.
A four-year programme links equipment and workflow software
Elekta develops systems that clinicians use to target cancers and selected neurological conditions with radiation. Its programme covers new treatment machines as well as planning, workflow-automation and precision-delivery software. That combination matters commercially: a hospital does not buy accuracy from one component alone. Imaging, planning, delivery and clinical workflow have to work together reliably enough for care teams to treat more patients without weakening quality controls.
The company says more than 2 million patients are treated with its technology each year across 130 countries. That installed base gives Elekta a route for deploying improvements, but it also raises the standard for execution. Hardware changes must fit clinical environments, while software updates need validation, integration and staff adoption. The loan therefore funds a multi-year product programme rather than a single launch, with value depending on whether Elekta can turn research spending into measurable gains in treatment precision and hospital throughput.
The loan shares a long development cycle
The EIB is financing up to half of the planned programme, leaving Elekta responsible for the remaining investment. The structure gives the Nasdaq Stockholm-listed company additional flexibility to fund research with long development timelines while keeping the programme anchored in existing Swedish and Dutch operations. It does not remove product or adoption risk: new systems still have to meet clinical, regulatory and procurement requirements before research expenditure becomes revenue.
The financing also reflects a policy objective. The EIB describes medical-technology R&D as vulnerable to underinvestment because of scientific uncertainty, long timelines and substantial upfront costs. For Elekta, public-bank debt can bridge that timing gap. The commercial test remains whether the resulting systems help providers increase capacity while preserving the accuracy and patient outcomes on which procurement decisions depend.
